260 related articles for article (PubMed ID: 31068372)
1.
Jones MR; Williamson LM; Topham JT; Lee MKC; Goytain A; Ho J; Denroche RE; Jang G; Pleasance E; Shen Y; Karasinska JM; McGhie JP; Gill S; Lim HJ; Moore MJ; Wong HL; Ng T; Yip S; Zhang W; Sadeghi S; Reisle C; Mungall AJ; Mungall KL; Moore RA; Ma Y; Knox JJ; Gallinger S; Laskin J; Marra MA; Schaeffer DF; Jones SJM; Renouf DJ
Clin Cancer Res; 2019 Aug; 25(15):4674-4681. PubMed ID: 31068372
[TBL] [Abstract][Full Text] [Related]
2.
Heining C; Horak P; Uhrig S; Codo PL; Klink B; Hutter B; Fröhlich M; Bonekamp D; Richter D; Steiger K; Penzel R; Endris V; Ehrenberg KR; Frank S; Kleinheinz K; Toprak UH; Schlesner M; Mandal R; Schulz L; Lambertz H; Fetscher S; Bitzer M; Malek NP; Horger M; Giese NA; Strobel O; Hackert T; Springfeld C; Feuerbach L; Bergmann F; Schröck E; von Kalle C; Weichert W; Scholl C; Ball CR; Stenzinger A; Brors B; Fröhling S; Glimm H
Cancer Discov; 2018 Sep; 8(9):1087-1095. PubMed ID: 29802158
[TBL] [Abstract][Full Text] [Related]
3. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
[TBL] [Abstract][Full Text] [Related]
5. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
[TBL] [Abstract][Full Text] [Related]
6. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract][Full Text] [Related]
7. NRG1 fusions in breast cancer.
Howarth KD; Mirza T; Cooke SL; Chin SF; Pole JC; Turro E; Eldridge MD; Garcia RM; Rueda OM; Boursnell C; Abraham JE; Caldas C; Edwards PAW
Breast Cancer Res; 2021 Jan; 23(1):3. PubMed ID: 33413557
[TBL] [Abstract][Full Text] [Related]
8. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
[TBL] [Abstract][Full Text] [Related]
9. Plain language summary of NRG1 fusions in cancer: current knowledge and treatment with afatinib and other drugs.
Liu SV
Future Oncol; 2022 Aug; 18(26):2865-2870. PubMed ID: 35876504
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic NRG1 Fusions: A New Hope for Targeted Therapy in Pancreatic Cancer.
Aguirre AJ
Clin Cancer Res; 2019 Aug; 25(15):4589-4591. PubMed ID: 31164372
[TBL] [Abstract][Full Text] [Related]
11. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer.
Umemoto K; Sunakawa Y
Crit Rev Oncol Hematol; 2021 Oct; 166():103465. PubMed ID: 34454058
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
Shin DH; Lee D; Hong DW; Hong SH; Hwang JA; Lee BI; You HJ; Lee GK; Kim IH; Lee YS; Han JY
Oncotarget; 2016 Oct; 7(43):69450-69465. PubMed ID: 27626312
[TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.
Liu SV; Frohn C; Minasi L; Fernamberg K; Klink AJ; Gajra A; Savill KMZ; Jonna S
Lung Cancer; 2024 Feb; 188():107469. PubMed ID: 38219288
[TBL] [Abstract][Full Text] [Related]
14. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in
Fusco MJ; Saeed-Vafa D; Carballido EM; Boyle TA; Malafa M; Blue KL; Teer JK; Walko CM; McLeod HL; Hicks JK; Extermann M; Fleming JB; Knepper TC; Kim DW
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250383
[TBL] [Abstract][Full Text] [Related]
15. Detection of NRG1 Gene Fusions in Solid Tumors.
Jonna S; Feldman RA; Swensen J; Gatalica Z; Korn WM; Borghaei H; Ma PC; Nieva JJ; Spira AI; Vanderwalde AM; Wozniak AJ; Kim ES; Liu SV
Clin Cancer Res; 2019 Aug; 25(16):4966-4972. PubMed ID: 30988082
[TBL] [Abstract][Full Text] [Related]
16. Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report.
Nie X; Zhang P; Bie Z; Song C; Zhang M; Ma D; Cui D; Cheng G; Li H; Lei Y; Su X; Wu W; Li L
World J Surg Oncol; 2023 Aug; 21(1):246. PubMed ID: 37587479
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic Neuregulin 1 gene (NRG1) fusions in cancer: A potential new therapeutic opportunities.
Zhang C; Mei W; Zeng C
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188707. PubMed ID: 35247506
[TBL] [Abstract][Full Text] [Related]
18. CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
Werr L; Plenker D; Dammert MA; Lorenz C; Brägelmann J; Tumbrink HL; Klein S; Schmitt A; Büttner R; Persigehl T; Shokat KM; Wunderlich FT; Schram AM; Peifer M; Sos ML; Reinhardt HC; Thomas RK
Mol Cancer Ther; 2022 May; 21(5):821-830. PubMed ID: 35247925
[TBL] [Abstract][Full Text] [Related]
19. CD74-NRG1 fusions in lung adenocarcinoma.
Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
[TBL] [Abstract][Full Text] [Related]
20. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
